Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support
Gebauer, Niklas, Biersack, Harald, Czerwinska, Ann-Cathrin, Schemme, Janina, Hardel, Tim Tristan, Bernard, Veronica, Rades, Dirk, Lehnert, Hendrik, Luley, Kim Barbara, Thorns, ChristophLanguage:
english
Journal:
Leukemia & Lymphoma
DOI:
10.3109/10428194.2015.1099648
Date:
November, 2015
File:
PDF, 754 KB
english, 2015